Niveen Hilal, PharmD
PGY2 Hematology/Oncology Practice Resident


Niveen Hilal is currently a PGY2 Pharmacy Resident at the University of Chicago Medicine. She completed her PGY1 at UCM. She graduated with her Doctor of Pharmacy from University of Illinois at Chicago. While studying at UIC, she worked as a pharmacy intern at an outpatient pharmacy, while serving as a leader in extracurricular activities on campus and throughout the community. In addition, she focused on renal transplant outcomes in diverse patient populations through various research projects as a pharmacy student. Her pharmaceutical interest is primarily focused on bone marrow transplant and leukemia, while exploring more research and philanthropic projects. She hopes to be able to build on her experience and education as a pharmacy resident at UCM.

PGY2 Research

Niveen’s PGY2 research project revolves around creating and establishing a tacrolimus protocol for patients who are status allogenic bone marrow transplant. The research project is titled, “Impact of the Implementation of a Pharmacist-Driven Tacrolimus Therapeutic Drug Monitoring Protocol.” The primary outcome of the project is to assess whether there are more therapeutic tacrolimus levels with the implementation of our therapeutic drug monitoring protocol. The TDM protocol incorporates direction on dose changes, drug-drug interactions, and the maintenance of adverse drug events. The secondary outcome focuses more on the unique toxicities of tacrolimus and the incidence of GVHD, AKI, relapse and other adverse events.


PGY1 Research

Niveen’s PGY1 Research project revolves around the revolutionizing immunotherapy agents and their relationship with inhaled corticosteroids. The research project is titled, “Impact of Inhaled Corticosteroids on Progression Free Survival in Patients with Metastatic Lung Cancer Receiving Immunotherapy.” The primary outcome of the project is to measure progression free survival in patients on various immunotherapy agents with and without inhaled corticosteroids (ICS). The secondary outcome focuses more on the unique toxicities of these agents and how the incidence is impacted by ICS, particularly pneumonitis.

The Value of the UChicago Program

The pharmacy residency program at UCM strives to challenge pharmacy residents in a clinical inpatient and outpatient setting in order for residents to reach their potential as a successful clinician. The rigorous on-call program allows residents full autonomy while assessing a wide array of patient cases in acute situations. UCM’s residency program will hone my skills as a clinical pharmacist in order to optimally treat patients.

My Favorite Aspects of the UChicago Program

  • Preceptors that are experts in their fields

  • Inter-disciplinary provider network

  • Several elective opportunities for rotations

  • Numerous prospects to precept students


  • Immunotherapy: Total Eclipse of the Heart

  • Impact of Inhaled Corticosteroids on Progression Free Survival in NSCLC patients

  • Adoptive T-Cell Therapy: More Money, More Problems?

  • Impact of a Clinical Pharmacist on TDM in BMT Patients



  • ODSC

  • Resident Development

  • Recruitment

  • Pharmacy Week

Resident's PGY2 Learning Experience Schedule

Module 1: Chemotherapy Clinic

Module 2: Supportive Oncology

Module 3: Bone Marrow Transplant

Module 4: Leukemia

Module 5: Pediatric Oncology

Module 6: Gynecology Oncology

Module 7: Immunocompromised Infectious Disease

Module 8: Palliative Care

Module 9: Bone Marrow Transplant Clinic

Resident's PGY1 Learning Experience Schedule

Module 1: Supportive Oncology

Module 2: Renal Transplant

Module 3: Internal Medicine

Module 4: PPE Staffing/TPN

Module 5: Leukemia

Module 6: Pharmacy Administration

Module 7: Antimicrobial Stewardship

Module 8: Cardiology

Module 9: Pediatric Intensive Care Unit

Module 10: Medical Intensive Care Unit

Module 11: PPE

Module 12: Anticoagulation Clinic

Contact Information: